SOM 1201
Alternative Names: SOM-1201Latest Information Update: 06 Nov 2020
At a glance
- Originator SOM Biotech
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Adrenoleucodystrophy; Adrenomyeloneuropathy
Most Recent Events
- 27 Oct 2020 Discontinued - Phase-I for Adrenoleucodystrophy in Spain (unspecified route) (SOM Biotech pipeline, October 2020)
- 27 Oct 2020 Discontinued - Phase-I for Adrenomyeloneuropathy in Spain (unspecified route) (SOM Biotech pipeline, October 2020)